目的 观察益气除痰方食药血清对顺铂耐药肺癌细胞A549/DDP增殖和细胞周期的影响.方法 制备益气除痰方含药血清和空白血清.分别用0(空白血清)、0.5%、1%、2.5%、5%、10%、20%、30%益气除痰方含药血清培养肺癌A549/DDP细胞,用MTT比色法测算增殖抑制率和半数抑制浓度(IC50).用0、50%IC50、100%IC50浓度益气除痰方含药血清培养肺癌A549/DDP细胞,用流式细胞术测算G0/G1期、S期、G2/M期细胞比例.结果 0.5%、1%、2.5%、5%、10%、20%、30%益气除痰方含药血清培养A549/DDP细胞48h后,细胞增殖抑制率分别为5.80%±0.95%、9.97%±1.26%、27.10%±3.22%、43.03%±2.02%、73.70%±4.69%、86.13%±1.59%、91.77%±1.65%,随着益气除痰方含药血清浓度增加,A549/DDP细胞增殖抑制率升高(P均<0.05),益气除痰方含药血清对A549/DDP细胞的IC50为8.56%.与益气除痰方含药血清浓度为0者比较,50%IC50和100%IC50浓度益气除痰方含药血清培养的A549/DDP细胞G0/G1期细胞比例增加,S期和G2/M期细胞比例降低,且药物浓度越高变化越显著(P均<0.05).结论 益气除痰方含药血清可抑制顺铂耐药肺癌A549/DDP细胞增殖,这可能与其阻滞A549/DDP细胞从G1期进入S期有关.
Objective To investigate the effects of Yiqi Chutan formula ( YQCTF) on proliferation and cell cycle of cisplatin-resistant human lung cancer cells A549/DDP.Methods The YQCTF serum and blank serum was made.The YQCTF serum containing 0, 0.5%, 1%, 2.5%, 5%, 10%, 20%and 30%YQCTF was used to culture the cisplatin-re-sistant A549/DDP cells.The proliferation inhibition rate and IC50 was evaluated by MTT assay.The YQCTF serum with the concentration of 0, 50%IC50 and 100%IC50 were used to culture the cisplatin-resistant A549/DDP cells, and the cell per-centages in the G0/G1 phase, S phase and G2/M phase.Results The proliferation inhibition rates were respectively 5.80%±0.95%, 9.97%±1.26%, 27.10%±3.22%, 43.03%±2.02%, 73.70%±4.69%, 86.13%±1.59%and 91.77%±1.65%when the A549/DDP cells were cultured with 0.5%, 1%, 2.5%, 5%, 10%, 20% and 30%YQCTF serum for 48 h.The proliferation inhibition rate was increased with the increasing concentrations of YQCTF serum (all P<0.05).IC50 was 8.56%.The cell percentage of A549/DDP cells in the G0/G1 phase was increased when the A549/DDP cells were cultured with the concentrations of 50%IC50 and 100%IC50 YQCTF serum as compared with 0 IC50 YQCTF serum.The percentage of A549/DDP cells in the S phase and G2/M phase was decreased, and the higher the con-centrations were, the more significant the changes would be (all P<0.05).Conclusion YQCTF serum could inhibit the proliferation of cisplatin-resistant human lung cancer cells A549/DDP, which may be related with its function of blocking cells from G1 phase to S phase.